Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors

Invasion and Metastasis

Volumn 18, Issue 5-6, 1998, Pages 271-284

  Tews, Dominique S ^a   Nissen, Anja ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cell adhesion; Gliomas; Proteases; Recurrence

Indexed keywords

CATHEPSIN D; CD44V ANTIGEN; COLLAGEN TYPE 4; FIBRONECTIN; GALECTIN 3; LAMININ; METALLOPROTEINASE; NERVE CELL ADHESION MOLECULE; TENASCIN;

ADULT; ARTICLE; ASTROCYTOMA; CARCINOMA IN SITU; CELL ADHESION; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR RECURRENCE;

EID: 0032456173     PISSN: 02511789     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024520     Document Type: Article

References (78)

1. Kleihues P, Soylemezoglu F, Schäuble B, Scheithauer BW, Burger PC: Histopathology, classification, and grading of gliomas. Glia 1995;15: 211-221.
2. Lang FF, Miller DC, Koslow M, Newcomb EW: Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81:427-436.
3. Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, Niederacher D, Wechsler W, Reifenberger G: Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 1996;55: 822-831.
4. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19-26.
5. Chiquet-Ehrismann R, Kalla P, Pearson CA, Beck K, Chiquet M: Tenascin interferes with fibronectin action. Cell 1988;53:383-390.
6. Giese A, Rief MD, Loo MA, Berens ME: Determinants of human astrocytoma migration. Cancer Res 1994;54:3897-3904.
7. Mahesparan R, Tysnes BB, Edvardsen K, Haugeland HK, Garcia Cabrera I, Lund-Johansen M, Engebraaten O, Bjerkvig R: Role of high molecular weight extracellular matrix proteins in glioma cell migration. Neuropathol Appl Neurobiol 1997;23:102-112.
8. Asher R, Bignami A: Hyaluronate binding and CD44 expression in human glioblastoma cells and astrocytes. Exp Cell Res 1992;203:80-90.
9. Radotra B, McCormick D, Crockard A: CD44 plays a role in adhesive interactions between glioma cells and extracellular matrix components. Neuropathol Appl Neurobiol 1994;20:399-405.
10. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T: Tenascin: An extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986;47:131-139.
11. Inohara H, Raz A: Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Res 1995;55:3267-3271.
12. Probstmeier R, Montag D, Schachner M: Galectin-3, a β-galactoside-binding animal lectin, binds to neural recognition molecules. J Neurochem 1995;64:2465-2472.
13. Herron GS, Werb Z, Dwyer K, Banda MJ: Secretion of metalloproteinases by stimulated capillary endothelial cells. I. Production of procollagenase and prostromelysin exceeds expression of proteolytic activity. J Biol Chem 1986;261:2810-2813.
14. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 1995;83:298-307.
15. Diment S, Stahl P: Macrophage endosomes contain proteases which degrade endocytosed protein ligands. J Biol Chem 1985;260:15311-15317.
16. Chintala SK, Gokaslan ZL, Go Y, Sawaya R, Nicolson GL, Rao JS: Role of extracellular matrix proteins in regulation of human glioma cell invasion in vitro. Clin Exp Metastasis 1996;14:358-366.
17. Friedlander DR, Zagzag D, Sniff B, Cohen H, Allen JC, Kelly PJ, Grumet M: Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves av and β1 integrins. Cancer Res 1996;56: 1939-1947.
18. Koochekpour S, Merzak A, Pilkington GJ: Extracellular matrix proteins inhibit proliferation, upregulate migration and induce morphological changes in human glioma cells lines. Eur J Cancer 1995;31A: 375-380.
19. Merzak A, Koocheckpour S, Pilkington GJ: CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res 1994;54:3988-3992.
20. Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, Okada Y: Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases-1 by human brain tumors. J Neurosurg 1994;81:69-77.
21. Okada H, Yoshida J, Sokabe M, Wakabayashi T, Hagiwara M: Suppression of CD44 expression decreases migration and invasion of human glioma cells. Int J Cancer 1996;66:255-260.
22. Kleihues P, Burger PC, Plate KH, Ohgaki H, Cavenee WK: Glioblastoma; in Kleihues P, Cavenee WK (eds): Pathology and Genetics. Tumours of the Nervous System. Lyon, International Agency for Research on Cancer, 1997, pp 16-24.
23. Ariza A, Lopez D, Matel JL, Isamat M, Musulen E, Pujol M, Ley A, Navas-Palacios JJ: Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: An immunohistochemistry study. Hum Pathol 1995;26:1144-1147.
24. Gingras MC, Roussel E, Bruner JM, Branch CD, Moser RP: Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 1995;57:143-153.
25. Kaaijk P, Troost D, Morsink F, Keehnen RMJ, Leenstra S, Bosch DA, Pals ST: Expression of CD44 splice variants in human primary brain tumors. J Neurooncol 1995; 26:185-190.
26. Kuppner MC, Van Meir E, Gauthier T, Hamou MF, de Tribolet N: Differential expression of the CD44 molecule in brain tumors. Int J Cancer 1992;50:572-577.
27. Pilkington GJ, Akinwunmi J, Ognjenovic N, Rogers JP: Differential binding of anti-CD44 on human gliomas in vitro. Neuroreport 1993; 4:259-262.
28. Ylagan LR, Quinn B: CD44 expression in astrocytic tumors. Mod Pathol 1997;10:1239-1246.
29. Eibl RH, Pietsch T, Moll J, Skroch-Angel P, Hieder KH, von Ammon K, Wiestler OD, Ponta H, Kleihues P, Herrlich P: Expression of variant CD44 epitopes in human astrocytic brain tumors. J Neurooncol 1995; 26:165-170.
30. Nagasaka S, Tanabe KK, Bruner JM, Saya H, Sawaya RE, Morrison RS: Alternative RNA splicing of the hyaluronic acid receptor CD44 in the normal human brain and in brain tumors. J Neurosurg 1995;82: 858-863.
31. Radotra B, McCormick D: Glioma invasion in vitro is mediated by CD44-hyaluronan interactions. J Pathol 1997;181:434-438.
32. Radotra B, McCormick D: CD44 is involved in migration but not spreading of astrocytoma cells in vitro. Anticancer Res 1997;17:945-949.
33. Giese A, Loo MA, Rief MD, Tran N, Berens ME: Substrates for astrocytoma invasion. Neurosurgery 1995;37:294-301.
34. Tysnes BB, Larsen LF, Ness GO, Mahesparan R, Edvardsen K, Garcia-Cabrera I, Bjerkvig R: Stimulation of glioma-cell migration by laminin and inhibition by anti-α3 and anti-β1 integrin antibodies. Int J Cancer 1996;67:777-784.
35. Chintala SK, Sawaya R, Gokaslan ZL, Fuller G, Rao JS: Immunohistochemical localization of extracellular matrix proteins in human glioma, both in vivo and in vitro. Cancer Lett 1996;101:107-114.
36. Bellon G, Caulet T, Cam Y, Pluot M, Poulin G, Pytlinska M, Bernard MH: Immunohistochemical localization of macromolecules of the basement membrane and extracellular matrix of human gliomas and meningiomas. Acta Neuropathol 1985;66:245-252.
37. Giordana MT, Germani I, Giaccone G, Mauro A, Migheli A, Schiffer D: The distribution of laminin in human brain tumors; an immunohistochemical study. Acta Neuropathol 1985;67:51-57.
38. McComb RD, Bigner DD: Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors. J Neurooncol 1985;3:181-186.
39. Rutka JT, Myatt CA, Giblin JR, Davis RL, Rosenblum ML: Distribution of extracellular matrix proteins in primary human brain tumours: An immunohistochemical analysis. Can J Neurol Sci 1987;14:25-30.
40. Schiffer D, Giordana MT, Mauro A, Migheli A: GFAP, F VIII/RAg, laminin, and fibronectin in gliosarcomas; an immunohistochemical study. Acta Neuropathol 1984;63: 108-116.
41. Girgrah N, Letarle M, Becker LE, Cruz TF, Theriault E, Moscarello MA: Localization of the CD44 glycoprotein to fibrous astrocytes in normal white matter and to reactive astrocytes in active lesions in multiple sclerosis. J Neuropathol Exp Neurol 1991;50:779-792.
42. Bresalier RS, Yan P-S, Byrd JC, Lotan R, Raz A: Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 1997; 80:776-787.
43. Gordower L, Decaestecker C, Kacem Y, Lemmers A, Gusman J, Burchert M, Danguy A, Gabius H-J, Salmon I, Kiss R, Camby I: Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol Appl Neurobiol 1999; 25:319-330.
44. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, von Deimling A: Shared allelic losses on chromosomes 1 p and 19q suggest a common origin of oligodendroglioma and olgoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-95.
45. Raff MC, Miller RH, Noble M: A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 1983;303:390-396.
46. Zagzag D, Friedlander DR, Dosik J, Chikramane S, Chan W, Greco MA, Allen JC, Dorovini-Zis K, Grumet M: Tenascin-C expression by angiogenic vessels in human astrocytes and by human brain endothelial cells in vitro. Cancer Res 1996;56: 182-189.
47. Bourdon MA, Wikstrand CJ, Furthmayer H, Matthews TJ, Bigner DD: Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal-antibodies. Cancer Res 1983;43:2796-2805.
48. Hasegawa K, Yoshida T, Matsumoto K, Katsuta K, Waga S, Sakakura T: Differential expression of tenascin-C and tenascin-X in human astrocytomas. Acta Neuropathol 1997;93:431-437.
49. Higuchi M, Ohnishi T, Arita N, Hiraga S, Hayakawa T: Expression of tenascin in human gliomas: Its relation to histological malignancy, tumor dedifferentiation and angiogenesis. Acta Neuropathol 1993;85: 481-487.
50. Zagzag D, Friedlander DR, Miller DC, Dosik J, Cangiarella J, Kostianovsky M, Cohen H, Grumet M, Greco MA: Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 1995;5:907-914.
51. Wehrle-Haller B, Chiquet M: Dual function of tenascin: Simultaneous promotion of neurite growth and inhibition of glial migration. J Cell Sci 1993;106:597-610.
52. End P, Panayotou G, Entwistle A, Waterfield MD, Chiquet M: Tenascin: A modulator of cell growth. Eur J Biochem 1992;209:1041-1051.
53. Crossin KL: Cytotactin binding: Inhibition of stimulated proliferation and intracellular alkalinization in fibroblasts. Proc Natl Acad Sci USA 1991;88:11403-11407.
54. Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME: Dichotomy of astrocytoma migration and proliferation. Int J Cancer 1996;67: 275-282.
55. Patel K, Frost G, Kiely F, Phimister E, Coakham HB, Kemshead JT: Expression of the cluster 1 antigen (neural cell adhesion molecule) in neuroectodermal tumours. Br J Cancer Suppl 1991;14:20-23.
56. Wolf HK, Buslei R, Blumcke I, Wiestler OD, Pietsch T: Neural antigens in oligodendrogliomas and dysembryoplastic neuroepithelial tumors. Acta Neuropathol 1997;94: 436-443.
57. Edvardsen K, Brunner N, Spang-Thomsen M, Walsh FS, Bock E: Migratory, invasive and metastatic capacity of NCAM transfected rat glioma cells. Int J Dev Neurosci 1993;11:681-690.
58. Edvardsen K, Chen W, Rucklidge G, Walsh FS, Öbrink B, Bock E: Transmembrane neural cell-adhesion molecule (NCAM), but not glycosyl-phosphatidylinositol-anchored NCAM, downregulates secretion of matrix metalloproteinases. Proc Natl Acad Sci USA 1993;90:11463-11467.
59. Gratsa A, Rooprai HK, Rogers JP, Martin KK, Pilkington GJ: Correlation of expression of NCAM and GD3 ganglioside ot motile behavior in neoplastic glia. Anticancer Res 1997;17:4111-4117.
60. Maidment SL, Rucklidge GJ, Rooprai HK, Pilkington GJ: An inverse correlation between expression of NCAM-A and the metalloproteinases gelantinase-A and gelantinase-B in human glioma cells in vitro. Cancer Lett 1997;116:71-77.
61. Obukhov SK, Gennie MJ, Tutt AL, Kemshead JT, Coakham HB, Beverely PC:.The cytotoxic action of lymphokine activated killer cells upon the human glioma cell line U251 is stimulated by bispecific-monoclonal antibody (MoAb) constructs. J Neurooncol 1992; 13:203-210.
62. Shimizu Y, VanSeventer GA, Horgan KJ, Shaw S: Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol 1990;145:59-67.
63. Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, McKerrow JH, Banda MJ: Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 1990;50:2322-2329.
64. Nakagawa T, Kubota T, Kabuto M, Fujimoto N, Okada Y: Secretion of matrix metalloproteinase-2 (72 kD gelatinase/type IV collagenase = gelatinase A) by malignant human glioma cell lines: Implications for the growth and cellular invasion of the extracellular matrix. J Neurooncol 1995;28:13-24.
65. Rao JS, Yamamoto M, Mohanam S, Gokaslan ZL, Fuller GN, Stetler-Stevenson WG, Rao VH, Liotta LA, Nicolson GL, Sawaya RE: Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 1996;14:12-18.
66. Sawaya RE, Yamamoto M, Gokaslan ZL, Wang SW, Mohanam S, Fuller GN, McCutcheon IE, Stetler-Stevenson WG, Nicolson GL, Rao JS: Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis 1996;14: 35-42.
67. Wesseling P, van der Laak JA, Link M, Teepen HL, Ruiter DJ: Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy. Hum Pathol 1998;29:352-358.
68. Yamamoto M, Mohanam S, Sawaya R, Fuller GN, Seiki M, Sato H, Gokaslan ZL, Liotta LA, Nicolson GL, Rao JS: Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996;56:384-392.
69. Del-Maestro RF, Vaithilingam IS, McDonald W: Degradation of collagen type IV by C6 astrocytoma cells. J Neurooncol 1995;24:75-81.
70. Robson DK, Ironside JW, Reid WA, Bogue PR: Immunolocalization of cathepsin D in the human central nervous system and central nervous system neoplasms. Neuropathol Appl Neurobiol 1990;16:39-44.
71. Sivaparvathi M, Sawaya R, Chintala SK, Go Y, Gokaslan ZL, Rao JS: Expression of cathepsin D during the progression of human gliomas. Neurosci Lett 1996;208:171-174.
72. Nishimura Y, Kawabata T, Kato K: Identification of latent procathepsins B and L in microsomal lumen: Characterization of enzymatic activation and proteolytic processing in vitro. Arch Biochem Biophys 1988; 261:64-71.
73. Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, Raz A: Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994;33: 14109-14114.
74. Liu FT, Hsu DK, Zuberi RI, Kuwabara I, Chi EY, Henderson WR Jr: Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 1995;147: 1016-1028.
75. Schabet M, Whitaker JN, Schott K, Stevens A, Zurn A, Buhler R, Wietholter H: The use of protease inhibitors in experimental allergic neuritis. J Neuroimmunol 1991;31: 265-272.
76. Giese A, Westphal M: Glioma invasion in the central nervous system. Neurosurgery 1996;39:235-250.
77. Paulus W, Baur I, Schuppan D, Roggendorf W: Characterization of integrin receptors in normal and neoplastic human brain. Am J Pathol 1993;143:154-163.
78. Tohma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O, Kleihues P, Ohgaki H: Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 1996;57:239-245.